What is the share price of Procter & Gamble Health Ltd (PGHL) today?
The share price of PGHL as on 18th September 2025 is ₹6265.50. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Procter & Gamble Health Ltd (PGHL) share?
The past returns of Procter & Gamble Health Ltd (PGHL) share are- Past 1 week: 0.10%
- Past 1 month: -0.66%
- Past 3 months: 5.28%
- Past 6 months: 20.27%
- Past 1 year: 22.36%
- Past 3 years: 51.07%
- Past 5 years: 18.82%
What are the peers or stocks similar to Procter & Gamble Health Ltd (PGHL)?
The peers or stocks similar to Procter & Gamble Health Ltd (PGHL) include:What is the dividend yield % of Procter & Gamble Health Ltd (PGHL) share?
The current dividend yield of Procter & Gamble Health Ltd (PGHL) is 1.97.What is the market cap of Procter & Gamble Health Ltd (PGHL) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Procter & Gamble Health Ltd (PGHL) is ₹10551.40 Cr as of 18th September 2025.What is the 52 week high and low of Procter & Gamble Health Ltd (PGHL) share?
The 52-week high of Procter & Gamble Health Ltd (PGHL) is ₹6739 and the 52-week low is ₹4863.What is the PE and PB ratio of Procter & Gamble Health Ltd (PGHL) stock?
The P/E (price-to-earnings) ratio of Procter & Gamble Health Ltd (PGHL) is 45.01. The P/B (price-to-book) ratio is 19.65.Which sector does Procter & Gamble Health Ltd (PGHL) belong to?
Procter & Gamble Health Ltd (PGHL) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Procter & Gamble Health Ltd (PGHL) shares?
You can directly buy Procter & Gamble Health Ltd (PGHL) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Procter & Gamble Health Ltd
PGHL Share Price
6,265.501.43% (-91.00)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
PGHL Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
PGHL Performance & Key Metrics
PGHL Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 35.10 | 19.65 | 1.97% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 37.23 | 5.88 | 0.58% |
PGHL Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
PGHL Company Profile
Procter & Gamble Health Limited, formerly Merck Limited, is engaged in manufacturing and marketing of pharmaceuticals, bulk drugs, fine chemicals and pigments
SUNPHARMA
PE Ratio
35.57
35.57
1Y Return
10.21%
10.21%
Buy Reco %
86.11
86.11
CIPLA
PE Ratio
23.89
23.89
1Y Return
4.44%
4.44%
Buy Reco %
66.67
66.67
TORNTPHARM
PE Ratio
62.83
62.83
1Y Return
6.19%
6.19%
Buy Reco %
76.00
76.00
DRREDDY
PE Ratio
19.30
19.30
1Y Return
0.70%
0.70%
Buy Reco %
40.00
40.00
MANKIND
PE Ratio
53.28
53.28
1Y Return
10.13%
10.13%
Buy Reco %
81.25
81.25
PGHL Sentiment Analysis
PGHL Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
PGHL Stock Summary · June 2025
The company demonstrated robust fiscal performance for the nine-month period ending March 31, 2025, with an 8% sales increase and a remarkable 27% rise in profit after tax, underscoring the effectiveness of its integrated growth strategy. Despite navigating a challenging macroeconomic landscape, management remains committed to enhancing product superiority and expanding market share, particularly through innovative e-commerce initiatives and a new distribution model aimed at rural outreach. The emphasis on consumer health, particularly addressing Vitamin B deficiency, has fostered positive market sentiment, bolstered by educational campaigns that raise awareness of product benefits. Continuous engagement with healthcare professionals and consumer feedback integration are pivotal in driving innovation and maintaining brand loyalty, positioning the company for sustained growth and operational excellence.
PGHL Stock Growth Drivers
PGHL Stock Growth Drivers
6Strong Financial Performance
The company has reported significant financial achievements, including an 8% increase in sales to Rs.
Effective Integrated Growth Strategy
The company's Integrated Growth Strategy has been pivotal in driving growth and profitability. It focuses
PGHL Stock Challenges
PGHL Stock Challenges
0
Hmm, looks like there are nochallenges
PGHL Forecast
PGHL Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
PGHL
PGHL
Income
Balance Sheet
Cash Flow
Annual Normal View
PGHL Income Statement
PGHL Income Statement
Annual Normal View
| Financial Year | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,424.75 | 1,026.83 | 1,127.60 | 1,248.01 | 1,166.89 | 944.52 | 1,287.29 | |||||||
Raw Materials | 444.47 | 310.39 | 344.55 | 358.99 | 329.69 | 247.75 | 864.18 | |||||||
| Power & Fuel Cost | 19.09 | 12.97 | 14.70 | 12.88 | 8.50 | 5.82 | ||||||||
| Employee Cost | 182.93 | 153.66 | 167.56 | 206.17 | 215.16 | 142.06 | ||||||||
| Selling & Administrative Expenses | 257.28 | 173.99 | 203.91 | 196.86 | 181.66 | 135.98 | ||||||||
| Operating & Other expenses | 136.68 | 111.70 | 116.01 | 130.04 | 130.44 | 84.17 | ||||||||
EBITDA | 384.30 | 264.12 | 280.87 | 343.07 | 301.44 | 328.74 | 423.11 | |||||||
| Depreciation/Amortization | 29.45 | 30.04 | 27.08 | 28.10 | 27.40 | 16.69 | 22.13 | |||||||
| PBIT | 354.85 | 234.08 | 253.79 | 314.97 | 274.04 | 312.05 | 400.98 | |||||||
| Interest & Other Items | 0.00 | 0.80 | 0.42 | 0.77 | 0.72 | 0.43 | 0.55 | |||||||
| PBT | 354.85 | 233.28 | 253.37 | 314.20 | 273.32 | 311.62 | 400.43 | |||||||
| Taxes & Other Items | 100.77 | 56.48 | 60.85 | 84.73 | 72.34 | 77.21 | 99.84 | |||||||
| Net Income | 254.08 | 176.80 | 192.52 | 229.47 | 200.98 | 234.41 | 300.59 | |||||||
| EPS | 153.07 | 106.51 | 115.98 | 138.24 | 121.08 | 141.22 | 181.09 | |||||||
| DPS | 230.00 | 130.00 | 52.50 | 95.00 | 260.00 | 125.00 | 140.00 | |||||||
| Payout ratio | 1.50 | 1.22 | 0.45 | 0.69 | 2.15 | 0.89 | 0.77 |
PGHL Company Updates
FY 2019FY 2019
PGHL Stock Peers
PGHL Past Performance & Peer Comparison
PGHL Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Procter & Gamble Health Ltd | 45.01 | 19.65 | 1.97% |
| Sun Pharmaceutical Industries Ltd | 35.57 | 5.36 | 0.99% |
| Cipla Ltd | 23.89 | 4.03 | 1.03% |
| Torrent Pharmaceuticals Ltd | 62.83 | 15.82 | 0.90% |
PGHL Stock Price Comparison
Compare PGHL with any stock or ETFCompare PGHL with any stock or ETF
PGHL
PGHL Holdings
PGHL Shareholdings
PGHL Promoter Holdings Trend
PGHL Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
PGHL Institutional Holdings Trend
PGHL Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
PGHL Shareholding Pattern
PGHL Shareholding Pattern
PGHL Shareholding History
PGHL Shareholding History
Foreign Institutions
Mutual Funds Invested in PGHL
Mutual Funds Invested in PGHL
No mutual funds holding trends are available
Top 5 Mutual Funds holding Procter & Gamble Health Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 4.1817% | Percentage of the fund’s portfolio invested in the stock 0.68% | Change in the portfolio weight of the stock over the last 3 months 0.07% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 125/247 (-45) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 2.2189% | Percentage of the fund’s portfolio invested in the stock 2.77% | Change in the portfolio weight of the stock over the last 3 months 0.39% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 66/128 (0) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.4543% | Percentage of the fund’s portfolio invested in the stock 5.36% | Change in the portfolio weight of the stock over the last 3 months 0.42% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 2/56 (+1) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing PGHL stock
smallcases containing PGHL stock
Looks like this stock is not in any smallcase yet.
PGHL Events
PGHL Events
PGHL Dividend Trend
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 1.97%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹19.66 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
PGHL Dividend Trend
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 1.97%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹19.66 every year
PGHL Upcoming Dividends
PGHL Upcoming Dividends
No upcoming dividends are available
PGHL Past Dividends
PGHL Past Dividends
Cash Dividend
Ex DateEx DateAug 22, 2025
Final
Final | Div/Share: ₹45.00
Dividend/Share
₹45.00
Ex DateEx Date
Aug 22, 2025
Cash Dividend
Ex DateEx DateFeb 21, 2025
Interim
Interim | Div/Share: ₹80.00
Dividend/Share
₹80.00
Ex DateEx Date
Feb 21, 2025
Cash Dividend
Ex DateEx DateNov 28, 2024
Final
Final | Div/Share: ₹60.00
Dividend/Share
₹60.00
Ex DateEx Date
Nov 28, 2024
Cash Dividend
Ex DateEx DateFeb 14, 2024
Interim
Interim | Div/Share: ₹50.00
Dividend/Share
₹50.00
Ex DateEx Date
Feb 14, 2024
Cash Dividend
Ex DateEx DateFeb 14, 2024
Special
Special | Div/Share: ₹150.00
Dividend/Share
₹150.00
Ex DateEx Date
Feb 14, 2024
PGHL Stock News & Opinions
PGHL Stock News & Opinions
Articles & Videos
Corporate
Procter & Gamble Health announces change in HR leadership
Procter & Gamble Health announced that Anit Singh will be stepping down from his position as the Company's Human Resource Leader, effective 30 September 2025, as he moves on to a regional role in P&G as Director- Humar Resources, SK II- Japan and Tokyo. Sanika Gokhale will take over as Human Resource Leader of the Company starting 01 October 2025. Sanika Gokhale has a Post Graduate Diploma in Human resource Management, from Xavier School of Management- Jamshedpur (2015) and Bachelors of Mass Media from Mumbai University. Ms. Gokhale has a work experience of 10 years, and has been associated with the P&G group for the last 7 years. Ms. Gokhale has handled multiple roles with increasing accountability in her 7 years with P leading Human Resources Operations; Business partnering for Category teams within the P&G group in India and most recently, leading India Talent Practice and E&I for the region.Powered by Capital Market - Live
2 days agoCapital Market - Live
Corporate
Procter & Gamble Health to convene AGM
Procter & Gamble Health announced that the Annual General Meeting(AGM) of the company will be held on 29 August 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Procter & Gamble Health standalone net profit rises 294.40% in the June 2025 quarter
Net profit of Procter & Gamble Health rose 294.40% to Rs 66.18 crore in the quarter ended June 2025 as against Rs 16.78 crore during the previous quarter ended June 2024. Sales rose 19.33% to Rs 338.74 crore in the quarter ended June 2025 as against Rs 283.88 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales338.74283.88 19 OPM %26.6717.00 - PBDT94.2550.18 88 PBT88.8143.02 106 NP66.1816.78 294 Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
P&G Health spurts after PAT climbs over threefold to Rs 66 cr in Q1 FY26
Revenue from operations jumped 19.33% to Rs 338.74 crore, driven by broad-based growth in domestic and exports business. Profit before tax (PBT) zoomed 289.01% to Rs 88.81 crore, compared with Rs 22.83 crore posted in same quarter last year. Milind Thatte, managing director, P&G Health India, said, We are pleased with the continued momentum and strong start to the Financial Year 2025-26. These results are a reflection of our commitment towards addressing the evolving needs of our consumers and healthcare professionals, via superior brand building and go to market initiatives while improving supply chain capabilities. He further added, 'Our strategy, centered on a focused portfolio of quality, trusted, and highly recommended brands where performance drives brand choice; superiority (across product, package, brand communication, retail execution and value), constructive disruption and an agile accountable organization, is delivering balanced and sustainable growth results. We continue to drive engagement for our consumers and healthcare professionals alike, through innovation backed by science and meaningful interventions to make life a little better every day.' Procter & Gamble Health (P&G Health) is one of India's largest VMS companies, manufacturing and marketing vitamins, minerals, and supplements products that include Neurobion, Livogen, SevenSeas, Evion, Polybion, and Nasivion.Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
Procter & Gamble Health Ltd Falls 2.2%
Procter & Gamble Health Ltd lost 2.2% today to trade at Rs 5650.05. The BSE Healthcare index is down 0.05% to quote at 44305.8. The index is up 0.71 % over last one month. Among the other constituents of the index, Windlas Biotech Ltd decreased 1.71% and Tarsons Products Ltd lost 1.7% on the day. The BSE Healthcare index went up 15.39 % over last one year compared to the 2.51% surge in benchmark SENSEX. Procter & Gamble Health Ltd has lost 3.24% over last one month compared to 0.71% gain in BSE Healthcare index and 1.75% rise in the SENSEX. On the BSE, 57 shares were traded in the counter so far compared with average daily volumes of 515 shares in the past one month. The stock hit a record high of Rs 6107.55 on 12 Jun 2025. The stock hit a 52-week low of Rs 4912.3 on 25 Oct 2024.Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Procter & Gamble Health to conduct board meeting
Procter & Gamble Health will hold a meeting of the Board of Directors of the Company on 1 August 2025.Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Board of Procter & Gamble Health recommends final dividend
Procter & Gamble Health announced that the Board of Directors of the Company at its meeting held on 29 May 2025, inter alia, have recommended the final dividend of Rs 45 per equity Share (i.e. 450%) , subject to the approval of the shareholders.Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Procter & Gamble Health standalone net profit rises 31.40% in the March 2025 quarter
Net profit of Procter & Gamble Health rose 31.40% to Rs 61.18 crore in the quarter ended March 2025 as against Rs 46.56 crore during the previous quarter ended March 2024. Sales rose 23.17% to Rs 310.99 crore in the quarter ended March 2025 as against Rs 252.48 crore during the previous quarter ended March 2024. ParticularsQuarter EndedMar. 2025Mar. 2024% Var. Sales310.99252.48 23 OPM %26.0226.71 - PBDT83.9069.56 21 PBT78.5362.72 25 NP61.1846.56 31 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Procter & Gamble Health declare Quarterly Result
Procter & Gamble Health will hold a meeting of the Board of Directors of the Company on 29 May 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Procter & Gamble Health standalone net profit rises 26.13% in the December 2024 quarter
Net profit of Procter & Gamble Health rose 26.13% to Rs 90.90 crore in the quarter ended December 2024 as against Rs 72.07 crore during the previous quarter ended December 2023. Sales declined 0.06% to Rs 309.77 crore in the quarter ended December 2024 as against Rs 309.97 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales309.77309.97 0 OPM %39.8532.79 - PBDT127.24106.64 19 PBT121.6999.72 22 NP90.9072.07 26 Powered by Capital Market - Live
7 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of -7.89%, vs industry avg of 9.99%
Over the last 5 years, market share decreased from 0.57% to 0.23%
Over the last 5 years, net income has grown at a yearly rate of -1.6%, vs industry avg of 20.01%